Wall Street is positive on Kala Pharmaceuticals Inc (KALA). On average, analysts give KALA a strong buy rating. The average price target is $ 19.857, which means analysts expect the stock to rise 418.46% over the next twelve months. This average ranking gives KALA an analyst rating of 65, which is better than 65% of stocks based on data compiled by Investors Observer.
Why are analyst ratings important?
Analysts know the inner workings of the companies they follow better than anyone except company management. You can learn a lot about a company by studying financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the companies they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains or disrupt purchasing habits. This allows traders to make decisions ** ahead ** of a quarterly report which could be worse than expected.
Investors Observer aggregates the ratings of all analysts covering a given stock, takes the average of those ratings, and then the percentiles rank the averages. This provides a much higher level of granularity than the three levels provided by traditional buy / hold / sell ratings.
What is happening with the shares of Kala Pharmaceuticals Inc today?
Kala Pharmaceuticals Inc (KALA) stock was up 0.66% while the S&P 500 fell -1.86% at 1:10 p.m. on Monday, July 19. KALA gained $ 0.03 from the previous closing price of $ 3.80 on volume of 1,168,526 shares. Over the past year, the S&P 500 has risen 30.59% while the KALA has fallen -64.67%. KALA has lost – $ 1.96 per share over the past 12 months. Click here for the full Kala Pharmaceuticals Inc. share report.